Study of highly sensitive C-reactive protein in type 2 diabetes mellitus and prediction of cardiovascular risk with glycemic status

Authors

  • T. Doraickannu Department of Medicine, Aarupadai Veedu Medical College, Puducherry, India
  • T. Sechassayana Department of Medicine, Aarupadai Veedu Medical College, Puducherry, India
  • S. Vithiavathi Department of Medicine, Aarupadai Veedu Medical College, Puducherry, India
  • Momin Varisali Department of Medicine, Hope Health Care, Gujarat, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20191472

Keywords:

CVD, Type 2 DM, HbA1c, hs-CRP

Abstract

Inflammation plays a vital role in accentuating the formation of atherosclerotic plaque in diabetes mellitus. So, the measurements of inflammatory markers provide a method of assessing cardiovascular risk. Among the inflammatory markers, highly sensitive C-reactive protein (hs-CRP) is used to detect the low-level inflammation when it is within the normal range. Also, hs-CRP measurement may be useful for assessment of the risk of complication in diabetes patients. So, the present study is conducted to measure plasma hs-CRP level in T2DM and to determine adequate glycaemic control reduces hs-CRP level. The objectives of this study were to correlate HbA1c and hs-CRP in T2DM and predict cardiovascular risk with glycaemic status.

Methods: Authors took 50 diabetic patients. The investigation includes FBS, PPBS, hs-CRP and HbA1c. hs-CRP is measured by immunoturbidimetry method. The reports were collected and compared with normal reference range.

Results: The correlation between hs-CRP levels and HbA1c level after six months show a significant relationship where mean HbA1c values on day 1 and after 6 months were 8.088±1.219 and 7.518±0.693 respectively. The hs-CRP values were 2.508±1.050 on day 1 and 2.15±0.927 after 6 months proving that better glycaemic controls decrease hs-CRP thereby decreasing cardiovascular risk.

Conclusions: hs-CRP values are directly related to HbA1c and better glycaemic control reduces risk of CVD.

Author Biography

Momin Varisali, Department of Medicine, Hope Health Care, Gujarat, India

Consulatant, Department of General Medicine.

References

Power AC. Diabetes mellitus: Diagnosis, classification and pathophysiology. In: Chapter 417 in Harrisons principles of internal medicine; Kasper DL, Fauci AS, Hauser SL, Lomgo DL, Jameson JL, Loscalzo J, eds. USA; McGrew- Hill: 19th ed; 2015;2:2399.

Centers for disease control and prevention. National diabetes statistics report: Estimates of diabetes and its burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services; 2014.

Rivellese AA, Riccardi G, Vaccaro O. Cardiovascular risk in women with diabetes. Nutrit Metabol Cardiovasc Dis. 2010;20(6):474-80.

Duncan B, Schmidt M, Pankow J, Ballantyne C. Atherosclerosis risk in communities study. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diab. 2003;52:1799-05.

Libby P. Mechanisms of acute coronary syndromes and their 11. implications for therapy. N Engl J Med. 2013;368:2004-13.

Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279:48487-90.

Roberts WL, CDC/AHA. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: laboratory tests available to assess inflammation-performance and standardization: a background paper. Circul. 2004;110:e572-6.

Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297(6):611-9.

Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70mg/dl and C-reactive protein <2mg/l: an analysis of the prove-it timi-22 trial. J Am Coll Cardio. 2005;45(10):1644-8.

Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circul. 1999;100(3):230-5.

Albert MA, Danielson E, Rifai N, Ridker PM, Prince investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (Prince): a randomized trial and cohort study. JAMA. 2001;286(1):64-70.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Eng J Med. 2008;359(21):2195.

American diabetes association. Erratum. classification and diagnosis of diabetes. Sec. 2. In standards of medical care in diabetes-2016. Diabetes Care. 2016;39(1):S13-22.

Yousuf O, Bibhu D, Martin S, Joshi H, Blaha J. High-sensitivity C-reactive protein and cardiovascular disease: J Am Coll Cardiol. 2013;62(5):397-08.

American Diabetes association. Consensus statement: role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diab Care. 1993;16:72-8.

Brownlee M, Cerami A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-21.

Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, et al. N ε-(carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochem. 1996;35(24):8075-83.

Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N. epsilon-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochem. 1995;34(34):10872-8.

Pfutzner A, Forst T. High sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diab Technol Ther. 2006;8(1):28-36.

Liu S, Manson J, Buring J, Stampfer M. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr. 2002;75:492-8.

Asegaonkar S, Marathe A, Tekade M, Cherekar L. High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile. J Diab Complic. 2011;25:368-70.

Deepak Y, Denis X, Alben S. High sensitivity C-reactive protein and cardiovascular disease: An Indian perspective. Indian J Med Res. 2015;142:261-8.

David C, Paul M. Clinical significance of hs-CRP in cardio vascular disease. Biomarkers in Medicine. Circulation. 2007;2:229-41.

Mishra DP, Das S, Sahu P. Prevalence of inflammatory markers (high-sensitivity C-reactive protein, nuclear factor-κB, and adiponectin) in Indian patients with type 2 diabetes mellitus with and without macrovascular complications. Meta Syndr Relat Dis. 2012;10:209-13.

Downloads

Published

2019-05-24

Issue

Section

Original Research Articles